NYSE:BAXBaxter International Stock Price, Forecast & News

Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BAX stock has increased by 9.3% and is now trading at $85.23. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International.

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Baxter International.

Baxter International will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Baxter International Inc (NYSE:BAX) announced its quarterly earnings data on Thursday, April, 30th. The medical instruments supplier reported $0.82 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.73 by $0.09. The medical instruments supplier had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.74 billion. Baxter International had a net margin of 8.85% and a return on equity of 22.70%. The business's revenue was up 6.2% on a year-over-year basis. During the same period last year, the firm earned $0.76 EPS. View Baxter International's earnings history.

Baxter International declared a quarterly dividend on Tuesday, May 5th. Stockholders of record on Friday, June 5th will be given a dividend of $0.245 per share on Wednesday, July 1st. This represents a $0.98 annualized dividend and a yield of 1.15%. The ex-dividend date is Thursday, June 4th. This is an increase from Baxter International's previous quarterly dividend of $0.22. View Baxter International's dividend history.

Baxter International announced that its board has initiated a stock repurchase program on Tuesday, November 13th 2018, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 6.1% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's management believes its stock is undervalued.

20 Wall Street analysts have issued twelve-month price objectives for Baxter International's shares. Their forecasts range from $84.00 to $105.00. On average, they expect Baxter International's share price to reach $96.60 in the next twelve months. This suggests a possible upside of 13.3% from the stock's current price. View analysts' price targets for Baxter International.

News stories about BAX stock have been trending very negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Baxter International earned a coverage optimism score of -3.6 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Baxter International.

Baxter International saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,030,000 shares, an increase of 31.3% from the June 15th total of 3,070,000 shares. Based on an average daily trading volume, of 3,100,000 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.8% of the company's shares are sold short. View Baxter International's Current Options Chain.

Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Insulet (PODD), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.03%), Fulton Breakefield Broenniman LLC (0.03%), Envestnet Asset Management Inc. (0.02%), Tsfg LLC (0.02%), Dalton Greiner Hartman Maher & Co. (0.02%) and Diversified Trust Co (0.01%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International.

BAX stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Envestnet Asset Management Inc., State of Alaska Department of Revenue, IFM Investors Pty Ltd, OLD Point Trust & Financial Services N A, Private Trust Co. NA, Farmers & Merchants Trust Co of Chambersburg PA, and Jacobs & Co. CA. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International.

BAX stock was acquired by a variety of institutional investors in the last quarter, including Fulton Breakefield Broenniman LLC, Canandaigua National Corp, DNB Asset Management AS, Everence Capital Management Inc., Carlson Capital Management, Exane Derivatives, NuWave Investment Management LLC, and Gofen & Glossberg LLC IL. View insider buying and selling activity for Baxter International.

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BAX stock can currently be purchased for approximately $85.23.

Baxter International has a market capitalization of $43.23 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

The official website for Baxter International is www.baxter.com.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]